Simultaneous Occurrence of Germline Mutations of SDHB and TP53 in a Patient with Metastatic Pheochromocytoma

被引:10
|
作者
Gniado, Ewa [1 ]
Carracher, Colin P. [1 ]
Sharma, Sona [1 ]
机构
[1] Univ Cincinnati, Div Endocrinol Diabet & Metab, Cincinnati, OH 45229 USA
来源
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2020年 / 105卷 / 04期
关键词
metastatic pheochromocytoma; SDHB mutation; TP53; mutation; MALIGNANT PHEOCHROMOCYTOMA;
D O I
10.1210/clinem/dgz269
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context. We describe a patient with metastatic malignant pheochromocytoma who was found to have germline SDHB and TP53 mutations occurring together. Case Description. A 39-year-old male presented with neck pain. Magnetic resonance imaging of the neck revealed a C3 vertebral body collapse and an underlying C3 lesion. Computed tomography (CT) of the thorax, abdomen, and pelvis showed multiple skeletal lesions, a sternal mass, bilateral pulmonary nodules, bilateral adrenal masses, and an aortocaval lymph node conglomerate. He underwent biopsy of the sternal mass, which revealed metastatic pheochromocytoma and subsequent blood work showed serum epinephrine levels of 200 pg/mL (normal 10-200 pg/mL), norepinephrine 28 241 pg/mL (normal 80-520 pg/mL), and dopamine 250 pg/mL (normal 0-20 pg/mL). Genetic testing revealed both SDHB and TP53 germline mutations. He was started on alpha- and beta-blockers and calcium channel blockers to control hypertension and tachycardia. Two months after the diagnosis, a CT of the abdomen and pelvis showed progression of disease, with enlargement of the right adrenal mass as well as the aortocaval conglomeration. His plasma metanephrines were significantly elevated. He was started on systemic chemotherapy with cyclophosphamide, dacarbazine, and vincristine. He required several antihypertensive agents, including metyrosine, to control his blood pressure in preparation for chemotherapy. Conclusion. This is the first reported case of simultaneous SDHB and TP53 germline mutations occurring in an individual with a highly aggressive clinical course of pheochromocytoma. We speculate that the simultaneous occurrence of these 2 oncogenic mutations may have led to an aggressive tumor progression.
引用
收藏
页码:991 / 995
页数:5
相关论文
共 50 条
  • [21] Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
    Li, Yanong
    Liu, Hailong
    Li, Tandy
    Feng, Jin
    He, Yanjiao
    Chen, Li
    Li, Chunde
    Qiu, Xiaoguang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Drastic Effect of Germline TP53 Missense Mutations in LiFraumeni Patients
    Zerdoumi, Yasmine
    Aury-Landas, Juliette
    Bonaiti-Pellie, Catherine
    Derambure, Celine
    Sesbouee, Richard
    Renaux-Petel, Mariette
    Frebourg, Thierry
    Bougeard, Gaelle
    Flaman, Jean-Michel
    HUMAN MUTATION, 2013, 34 (03) : 453 - 461
  • [23] Relative frequency and morphology of cancers in carriers of germline TP53 mutations
    Birch, JM
    Alston, RD
    McNally, RJQ
    Evans, DGR
    Kelsey, AM
    Harris, M
    Eden, OB
    Varley, JM
    ONCOGENE, 2001, 20 (34) : 4621 - 4628
  • [24] Characterization of germline TP53 splicing mutations and their genetic and functional analysis
    Varley, JM
    Attwooll, C
    White, G
    McGown, G
    Thorncroft, M
    Kelsey, AM
    Greaves, M
    Boyle, J
    Birch, JM
    ONCOGENE, 2001, 20 (21) : 2647 - 2654
  • [25] High prevalence of germline TP53 mutations in young osteosarcoma cases
    Mirabello, Lisa J.
    Yeager, Meredith
    Mai, Phuong L.
    Gastier-Foster, Julie
    Gorlick, Richard
    Khanna, Chand
    Patino-Garcia, Ana
    Sierrasesumaga, Luis
    Lecanda, Fernando
    Andrulis, Irene L.
    Wunder, Jay S.
    Gokgoz, Nalan
    Barkauskas, Donald A.
    Zhang, Xijun
    Vogt, Aurelie
    Jones, Kristine
    Boland, Joseph F.
    Chanock, Stephen J.
    Savage, Sharon A.
    CANCER RESEARCH, 2015, 75
  • [26] Germline TP53 mutations: the predominant genetic cause of adrenocortical carcinoma
    Renaux-Petel, M.
    Charbonnier, F.
    Tournier, I.
    Lienard, G.
    Bou, J.
    Kasper, E.
    Leheup, B.
    Mansuy, L.
    Guerrini-Rousseau, L.
    Brugieres, L.
    Liard-Zmuda, A.
    Baert-Desurmont, S.
    Frebourg, T.
    Bougeard, G.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1105 - 1105
  • [27] Characterization of germline TP53 splicing mutations and their genetic and functional analysis
    J M Varley
    C Attwooll
    G White
    G McGown
    M Thorncroft
    A M Kelsey
    M Greaves
    J Boyle
    J M Birch
    Oncogene, 2001, 20 : 2647 - 2654
  • [28] NO GERMLINE TP53 MUTATIONS DETECTED IN FAMILIAL AND BILATERAL TESTICULAR CANCER
    HEIMDAL, K
    LOTHE, RA
    LYSTAD, S
    HOLM, R
    FOSSA, SD
    BORRESEN, AL
    GENES CHROMOSOMES & CANCER, 1993, 6 (02): : 92 - 97
  • [29] High prevalence of gastric cancer in families with germline TP53 mutations
    Masciari, Serena
    Dewanwala, Akritti
    Stoffel, Elena M.
    Li, Frederick
    Garber, Judy E.
    Syngal, Sapna
    GASTROENTEROLOGY, 2008, 134 (04) : A67 - A67
  • [30] Cutaneous pleomorphic fibromas arising in patients with germline TP53 mutations
    Cloutier, Jeffrey M.
    Shalin, Sara C.
    Lindberg, Matthew
    Gardner, Jerad M.
    Fernandez-Pol, Sebastian
    Zaba, Lisa
    Novoa, Roberto
    Brown, Ryanne A.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2020, 47 (08) : 734 - 741